Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8 H -purin-8-one Inhibitors of DNA-PK.

Autor: Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ting AKT; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Finlay MRV; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Harmer AR; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Adeyemi OB; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Nordell P; Biopharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden., Cronin AS; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cadogan EB; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Davies BR; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2022 Jul 07; Vol. 13 (8), pp. 1295-1301. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).